Dorsey Brian's Form 4 filing
ARS Pharmaceuticals, Inc. (SPRY) · filed Nov 14, 2025
- Accession no.
- 0001380762-25-000005
- Filed
- Nov 14, 2025
- Trade date
- Nov 13, 2025
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $190.1K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Dorsey BrianCIK 0001380762 | Officer (Chief Operating Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 13, 2025 | Common Stock | MOption exerciseAcquired | +21,828 | $0.64 | +$13,969.92 | 32,617 | Direct | |
| Nov 13, 2025 | Common Stock | SSaleDisposed | −21,828 | $8.71F2 | −$190,121.88 | 10,789 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 13, 2025 | Common Stock | MOption exerciseDisposed | −21,828 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The weighted average sale price for the transaction report was $8.7067, and the range of prices was between $8.63 and $8.835. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Referenced by the price of 1 transaction in Table I.